Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human collagen + silver nanoparticles is a **combination wound-healing biomaterial** that pairs bioengineered human collagen with antimicrobial silver nanoparticles, typically for topical use in dressings, gels, hydrogels, films, or wound matrices. The recombinant human collagen component primarily acts as a biocompatible extracellular-matrix scaffold that supports cell adhesion, granulation tissue formation, re-epithelialization, and tissue repair, while the silver nanoparticle component provides broad antimicrobial activity through local silver ion release and microbicidal effects on wound pathogens. Based on the available literature, this term appears to refer to a **product concept or formulation category rather than a single uniquely identified marketed drug**, and published uses are mainly in wound care, burn repair, postoperative healing, and other skin or soft-tissue injury settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human collagen + silver nanoparticles.